BioLineRx Ltd.
BLRX
Rank in Stocks
#29251
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and... BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Share Price
$0.00314174
Last synced: 2026-11-11
Market Cap
$8.37M
Change (1 day)
-0.76%
Change (1 year)
-47.08%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade BioLineRx Ltd. (BLRX)
Category
Healthcare
Operating Margin for BioLineRx Ltd. (BLRX)
Operating Margin as of November 2026 TTM: -874.34%
According to BioLineRx Ltd.'s latest financial reports, its current operating margin (TTM) is -874.34%. At the end of 2025 the company had an operating margin of -871.78%.
Operating Margin history for BioLineRx Ltd. from 2010 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -874.34% | 0.29% |
| 2025 | -871.78% | 1,136.22% |
| 2024 | -70.52% | -93.19% |
| 2023 | -1,035.29% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
| 2011 | 0.00% | -100.00% |
| 2010 | 11.61% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.04% |
US
|
|
| -149.01% | -99.83% |
US
|
|
| 25.57% | -100.03% |
AU
|
|
| 31.23% | -100.04% |
BE
|
|
| 29.35% | -100.03% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about BioLineRx Ltd.'s operating margin
What is BioLineRx Ltd.'s operating margin?
BioLineRx Ltd.'s operating margin is -874.34%, as of Nov 2026.
What was BioLineRx Ltd.'s operating margin in 2025?
In 2025, BioLineRx Ltd.'s operating margin was -871.78%, compared with -70.52% in 2024.
How has BioLineRx Ltd.'s operating margin changed since 2020?
From 2020 to 2025, BioLineRx Ltd.'s operating margin was highest in 2022 (0.00%) and lowest in 2023 (-1,035.29%).
How does BioLineRx Ltd.'s operating margin compare with similar companies?
BioLineRx Ltd.'s operating margin (-874.34%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.